Fluidic Sciences relaunches Microfluidic Diffusional Sizing technology to refine protein-protein interaction analysis

Published: 20-May-2024

The Microfluidic Diffusional Sizing (MDS) technology allows scientists better options when characterising a protein's biophysical properties

After its recent launch, Fluidic Sciences is debuting the acquired Fluidity One-M instrument for measuring protein-protein interactions in solution — leveraging Microfluidic Diffusional Sizing (MDS) technology.

The entry of Fluidic Sciences into the market gives scientists a new option for enhanced protein biophysical characterisation — advancing biopharmaceutical R&D in areas such as membrane protein characterisation, vaccine responses, monoclonal therapeutic antibodies and targeted protein degradation.


MDS for the easy characterisation of protein interactions

MDS technology stands out as a robust and easy method for characterising protein interactions in solution, as it doesn’t require immobilisation or purification of the samples like traditional methods. 

One can use MDS to quantify protein-protein interactions even in mixtures such as serum, cell lysates, or proteins in nanodiscs, making it possible to study protein native structures and activities.

Another hallmark benefit of MDS lies in its ability to simultaneously determine protein molecular size, binding affinity, and concentration of binding partners, which is suitable for analysing unknown antibody concentration in serum. 

MDS can also measure stoichiometry and reveal the mechanism of protein interactions.

The Fluidity One-M instrument, equipped with in-built MDS technology, has been extensively utilised in many publications and projects. These cover different applications, including profiling the immune response to SARS-CoV-2 variants and studying the aggregation of the α-Synuclein protein associated with Parkinson’s disease. 


New beginnings

MDS and the Fluidity One-M instrument were originally developed by Fluidic Analytics Ltd., which entered administration in November 2023, ceasing trading later in the month. Fluidic Sciences has acquired the Fluidity One-M instrument and associated assets from the administrators.

“Fluidic Analytics’ administration was unfortunate, but the core technology is excellent and we believe we can add to its capabilities. There are already 30 to 40 international customers who find the instrumentation very useful, so we can build on a sound base.” said David Newble, Board Member at Fluidic Sciences.

After extensive efforts to revamp and reform the acquired assets, Fluidic Sciences will simultaneously begin delivery of One-M consumables to existing customers as well as offer Fluidity One-M instruments to new customers seeking cutting-edge protein-protein interaction analysis solutions.


You may also like